Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNX-2110
- Development stage
- Unknown
- Lead developer
- Tonix Pharmaceuticals
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
TNX-2110 is a synthetic peptide mixture representing epitopes of multiple proteins from the SARS-CoV-2 virus. It is one component of the investigational diagnostic skin test TNX-2100, which is designed to measure delayed-type hypersensitivity (DTH) as an indicator of T cell immunity to SARS-CoV-2. The test involves intradermal administration and aims to distinguish between individuals with prior infection or exposure (who would respond to all three peptide mixtures in the test) and those who are only vaccinated (who would respond primarily to spike protein peptides). TNX-2110 specifically covers multiple antigens beyond just the spike protein, providing a broader assessment of immune response. The product is being developed by Tonix Pharmaceuticals for use as a diagnostic tool rather than as a therapeutic drug.
- Other names
- SARS-CoV-2 multi-antigen peptidesSARS-CoV2 multi-antigen peptidesSARS-CoV 2 multi-antigen peptides
02
Targets
γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on TNX-2110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNX-2110.